Completed PHASE2 INTERVENTIONAL NCT00036179

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

An Open-Label, Non-Comparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Sponsor: Astellas Pharma Inc

Interventions FK463

Updated 8 times since 2017 Last updated: Jan 8, 2018 Started: Feb 27, 1999 Primary completion: Jan 27, 2002 Completion: Jan 27, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00036179, this PHASE2 trial focuses on Candidiasis and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 8 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jan 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Créteil, France , Frankfurt, Germany , Genova, Italy , Graz, Austria , Huddinge, Sweden , Kaiserslautern, Germany , Leipzig, Germany , Linz, Austria , London, United Kingdom and 11 more locations